Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mirko Stanetić has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pembrolizumab in the treatment of non-small cell lung cancer—experiences from clinical practice

    by Lora Novakovic Lackovic, Milica Srecic Tomic, Marko Novakovic, Mirko Turic, Aleksandra Kajkut, Teodora Macinkovic, Mirko Stanetic, Ranko Glamocak

    Background: Immune checkpoint inhibitors (ICIs) have become the standard first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) without targetable mutations. This study aimed to assess real-world outcomes of pembrolizumab monotherapy in patients with high PD-L1 expression (≥50%) and compare them with results from the KEYNOTE-024 clinical trial.Methods: This retrospective study included patients with advanced or metastatic NSCLC treated with pembrolizumab as first-line therapy at the Clinic for Pulmonary Diseases, University Clinical Center of Republika Srpska, between January 2018 and December 2022. Clinical and pathological data were collected from medical records and analyzed using descriptive and inferential statistical methods.Results: The cohort included 46 patients with a median age of 64 years; 56.5% were aged ≥65, 73.9% were male, 76% were smokers, and 72% had an ECOG performance status of 1. Adenocarcinoma (AC) and squamous cell carcinoma (SCC) were diagnosed in 50 and 46% of cases, respectively, while 70% had metastatic disease and 15% had brain metastases. The two-year objective response rate (ORR) was 72.2%, lower than the 85.7% reported in KEYNOTE-024, possibly due to differences in PD-L1 assay (SP263 vs. 22C3) and patient selection. Despite this, the median overall survival (OS) was 36 months—higher than in the trial. One-, two-, and three-year survival rates were 57.9, 53.5, and 42.8%, respectively.Conclusion: Our findings confirm the clinical benefit of pembrolizumab in a real-world setting, despite lower ORR compared to clinical trial data. However, the prognosis remains guarded due to the advanced stage and comorbidities of the population. Further investigation is warranted to optimize patient selection and treatment strategies.


  • Prevalencija predijabetesa kod odraslih predgojaznih i gojaznih osoba i utvrđivanje njihovog rizika za obolijevanje od dijabetesa

    by Jzu Dom Zdravlja Banja Luka, Kosana Stanetić, Dijana Tomić Prodanović, JZU Dom zdravlja „Sveti Sava Teslić, Verica Petrović, Radojka Bijelić, Mirko Stanetić, Univerzitet U Banjoj Luc Medicinski Fakultet, Marijana Radanović Knežević, Jzu Dom Zdravlja Prijedor

    Introduction: Prediabetes is a state of impaired glucose homeostasis manifested either by an increase in fasting glucose or a decrease in glucose tolerance. Prediabetes carries a high risk of developing diabetes and cardiovascular complications. Aim: to determine the prevalence of prediabetes in pre-obese and obese individuals and the ten-year risk of developing T2DM in these subjects. Methods: The study was conducted in the family medicine clinics of the Educational Center for Family Medicine (ECFM) of the Banja Luka Health Center and the Tesliü Health Center. The study included pre-obese and obese patients older than 18 years of age, with a body mass index greater than 27.0 kg/m2. The research instrument was a questionnaire with sociodemographic data, a questionnaire for assessing the risk of developing diabetes mellitus type 2 (FINDRISC), and patient anthropometric measurements, arterial blood pressure measurements and laboratory findings (fasting glucose, lipid status, HbA1c) were performed. Results: The research included 264 patients. The prevalence of prediabetes in obese patients is 28.03%, while in pre-obese it is 21.21%. Subjects with a larger waist circumference are more likely to have prediabetes. With increasing age, the chance of getting prediabetes increases, over 30% of obese and pre-obese people who are over 70 years old have prediabetes. In relation to gender, women have a higher chance of developing prediabetes. Data from the FINDRISC questionnaire showed that 1.52% of patients from the pre-obese category have a 50% chance of developing diabetes within ten years, while 13.6% of obese patients have a 50% chance of developing T2DM within ten years. Conclusion: The role of family medicine doctors is in early identification of patients with prediabetes and diabetes, reduction of risk factors and possibly pharmacological treatment of these patients.

  • Open Access

    Prognostic value of tumor-infiltrating T-lymphocytes density in the therapeutic response to initial platinum-based chemotherapy in patients with non-small cell lung cancer

    by Lora Novakovic-Lackovic, Ljilja Latinovic-Tadic, Mirko Stanetic, Marko Lackovic

    Background/Aim. The fact that lung carcinomas, like other solid tumors, can be immunogenic may have a substantial prognostic value in non-small cell lung cancer (NSCLC). Specific cytotoxic T-lymphocytes (CTL) can be demonstrated in most patients with primary tumors of different histological types. Two main groups of T-lymphocytes participate in the coupled recognition of tumor-specific antigens ? CTL (CD8+) and helper T-lymphocytes (CD4+). The aim of the study was to assess the relationship between the tumor infiltration of T-lymphocytes and the therapeutic response to initial chemotherapy. Methods. Data were obtained from patients with NSCLC whose therapeutic response after four cycles of initial platinum-based chemotherapy was observed in relation to the density of tumor-infiltrating T-lymphocytes (CD4+ and CD8+) in small tumor biopsy samples. The therapeutic response was assessed in line with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 therapeutic response evaluation system. Based on the expected therapeutic response, the patients were divided into three groups: favorable therapeutic response patients (complete and partial regression), stable disease patients, and disease progression patients. To assess the density of CD4+ and CD8+ T-lymphocytes, the number of lymphocytes was determined at ?200 magnification (1.1 mm2). Three visual fields with the densest lymphocyte infiltrate were selected for counting, and the values of all individual fields were added up. Based on the mean value, the samples were classified into the following groups: score 0, score 1, score 2, and score 3. During statistical data processing, low infiltration density combined score 0 and score 1 groups, and high infiltration density combined score 2 and score 3 groups. Based on the collected data, a database was created in SPSS 22.0 software and used for further statistical analysis. Statistical analysis of the data included descriptive and analytical statistics methods. Results. There was no significant difference in the distribution of CD4+ T-lymphocytes and CD8+ T-lymphocytes in the epithelial component of the tumor between patients with a different therapeutic response (?2 = 2.977; p = 0.226 and ?2 = 1.329; p = 0.515, respectively). There was no significant influence of the infiltration density of CD4+ T-lymphocytes and CD8+ T-lymphocytes in the stromal component of the tumor on the therapeutic response (?2 = 0.606; p = 0.739 and ?2 = 5.167; p = 0.076, respectively). Conclusion. The research did not prove that patients with a high level of tumor-infiltrating CD4+ and CD8+ T-lymphocytes in the epithelial and stromal component of the NSCLC had a better therapeutic response to standard initial chemotherapy.


  • ASSESSMENT OF THE PRESENCE OF ANXIETY, DEPRESSION AND STRESS IN PATIENTS WITH CHRONIC DISEASES

    by Kosana Stanetić, Davorka Pleća, Verica Petrović, Suzana Savić, Mirko Stanetić

    Uvod: Depresivnost, anksiozonost i stres predstavljaju značajan javnozdravstveni problem kako u svijetu, tako i u Republici Srpskoj. Ovi mentalni poremećaji se učestalije javljaju kod pacijenata oboljelih od hroničnih bolesti. Cilj: Ispitati zastupljenost depresivnosti, anksioznosti i stresa kod oboljelih od hroničnih bolesti (hipertenzija, astma, hronična obstruktivna bolest pluća, dijabetes melitus, maligne bolesti, stanje poslije infarkta miokarda). Ispitati uticaj sociodemografskih faktora (pol, dob, stručna sprema, sadašnji radni status, porodični status) na prevalenciju depresivnosti, anksioznosti i stresa. Ispitati korišćenje anksiolitika za smanjenje prisutnih simptoma. Materijal i metode: Istraživanje je studija presjeka, provedena anketiranjem pacijenata starijih od 18 godina registrovanih u timovima porodične medicine Domu zdravlja Banja Luka u periodu od 1.08.2018. do 1.04.2019. Za procjenu postojanja anksioznosti, depresivnosti i stresa korištena je DASS– 21 skala, sociodemografski podaci su upisivani u samostalno kreiran upitnik. Pacijenti su izabrani iz registra pacijenata sa hroničnim bolestima. Rezultati: Istraživanjem je obuhvaćeno 405 pacijenata oboljelih od hroničnih bolesti. U odnosu na pacijente oboljele od drugih hroničnih bolesti u grupi pacijenata nakon infarkta miokarda statistički značajno najviše je bila izražena depresivnost (p=0.008, 95% CI 8.761-14.412); anksioznost (P= 0.002, 95% CI 19.2444-15.2038) i stres (p=0.016, 95% CI 13.130-18.655). U grupi pacijenata sa hroničnim bolestima 156 (38,5%) pacijenata koristi lijekove za smanjenje tegoba. Zaključak: Rezultati našeg istraživanja su pokazali visok nivo stresa, anksioznosti i depresivnosti kod pacijenata oboljelih od hroničnih bolesti, što upućuje na potrebu preduzimanja mjera za smanjenje stepena ovih mentalnih poremećaja.

  • Open Access

    The Influence of Different Risk Factors on COVID-19 Outcomes in Adult Patients - An Observational-Descriptive Study

    by Kosana Stanetić, Bojan Stanetić, Verica Petrović, Brankica Marković, Vesna Kević, Nevena Todorović, Mirko Stanetić

    Objective. The aim of our study was to investigate the predictors of morbidity (age, gender, smoking habits, obesity and the presence of chronic diseases) and COVID-19 outcomes. Subjects and Methods. The research was an observational descriptive study, conducted at The Family Medicine Education Center, The Primary Health Care Center, Banja Luka, in the period from 26th June to 31st December 2020. During the research period, seven family medicine teams followed their patients with COVID-19, and recorded possible predictors for morbidity and their influence on the disease outcome. Results. The study included 934 patients, 46.90% of whom were male. The majority of subjects were non-smokers and overweight. Diabetes was found in 5.57% patients, hypertension in 29.44%, chronic respiratory diseases in 5.25%, cancer in 4.39% patients. In the observed sample, 29.23% subjects contracted pneumonia, 18.52% were hospitalized, while 19 (2.03%) patients with severe clinical features had a fatal outcome. Multivariable regression analysis showed a high risk of pneumonia in male patients [OR=2.45, 95% CI (1.73-3.46)], elderly [OR= 1.07, 95% CI (1.06-1.09)] and obese patients with Body Mass Index ≥30.0 kg/m2 [OR=2.55, 95% CI (1.73-3.77)]. Male gender [OR=2.19, 95% CI (1.11-4.31)], older age [OR=1.08, 95% CI (1.05-1.11)] and hypertension [OR=2.51, 95% CI (1.06-5.91)] were the most important predictors for the development of severe clinical features in COVID 19. The statistically significant predictors of mortality were male gender [OR=7.16, 95% CI (1.56-32.86)] and older age [OR=1.12, 95% CI (1.06-1.18]. Conclusion. Being familiar with the predictors of morbidity and poor outcome in COVID-19 is helpful for carrying out preventive measures, early diagnosis and treatment of risk groups of patients.


  • Open Access

    High-sensitive troponin-T as a predictive outcome factor in COVID-19 hospitalised patients: Analysis after one-year follow-up

    by Darko Stojanović, Živko Ćetojević, Boris Dujaković, Mirko Stanetić, Tamara Kovačević-Preradović, Bojan Stanetić

    Introduction: Since December 2019, the humanity is constantly under affection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite global dissemination, neither the treatment or the specific predictive factors have been found or strictly defined yet. Aim: Aim of this study was to assess the long-term (1 year) predictive value of high-sensitive Troponin T (hsTnT) in COVID-19 affected, hospitalised patients. Methods: Between 5 March 2020 and 31 March 2020, 87 consecutive patients hospitalised at University Clinical Centre of the Republic of Srpska due to SARS-CoV2caused pneumonia, in whom hsTnT was measured, were included. The Kaplan-Meier analysis was used to assess differences in all-cause mortality between the groups. Independent predictors of all-cause mortality were identified through univariateand multivariate Cox regression analysis. Results: Compared with patients who had normal hsTnT levels, patients with raised hsTnT were significantly older (70.7 ± 13.23 vs 49 ± 15.29; p < 0.001). Glucose values were significantly increased in patients with raised hsTnT (9.29 ± 5.14 vs 6.76 ± 2.46 [4.1-5.9] mmol/L; p = 0.005), as well as serum creatinine (179.07 ± 225.58 vs 87.53 ± 18.16 µmol/L; p = 0.01), hsTnT (187.43 ± 387.29 vs 7.58 ± 3.40 pg/mL; p = 0.003), D-dimer (5.94 ± 13.78 vs 1.04 ± 1.26 [0-0.50] mg/L; p = 0.024), C-reactive protein (125.92 ± 116.82 vs 69.97 ± 73.09) [< 5.0] mg/L; p = 0.009) and calcium (1.32 ± 0.46 vs 1.03 ± 0.173 [2.20-2.65] mmol/L; p = 0.001). Kaplan-Meier analysis revealed that the number of all-cause deaths at 1 year was 19 of whom 18 were presented with elevated hsTnT (log-rank p < 0.001). When univariate Cox regression was applied, multiple predictors of all-cause mortality have been identified ie age, haemoglobin, haematocrit, urea, CK-MB as well as hsTnT. In a multiple regression model, hsTnT remained an independent predictor of poor outcome. Conclusion: Results from this study showed that the value of hsTnT during hospitalisation is possibly associated with long-term poor outcome of COVID-19 patients. Therefore, hsTnT may appear as a surrogate factor to differentiate between patients at high risk who need more intensive follow-ups.

  • Impact of pharmacist’s intervention on decreasing erlotinib interactions in the treatment of lung cancer patients in low resource settings

    by Tijana Kovacevic, Sandra Vezmar Kovacevic, Mirko Stanetic, Pedja Kovacevic, Branislava Miljkovic

    Background: This study aimed to demonstrate that having clinical pharmacist as a member of oncology team in low and middle income countries might lead to significant reduction in the number of erlotinib interactions in the treatment of non-small cell lung cancer patients. Methods: A group of 44 patients was labeled as intervention group and they were analyzed prospectively in the period from 1 January 2017 to 1 May 2018 during clinical pharmacist’s participation in regular weekly multidisciplinary oncology team meetings. The control group consisted of 44 out of 110 patients treated with erlotinib before the involvement of a clinical pharmacist in oncology team, match paired with 44 patients in intervention group. Results: Clinically significant interactions were identified in two-thirds of studied patients (57 out of 88). Most drug interactions, 38%, potentially result in decrease of serum concentration of erlotinib. Clinical pharmacist provided therapy modification suggestions for 32 out of 44 (72.72%) patients in the intervention group, most of which were accepted by doctors. In the intervention group, there were significantly less clinically significant interactions compared to the control group (10 versus 24, p = 0.002). Progression-free survival was significantly longer in the pharmacist’s intervention group (p = 0.001). Conclusions: Clinical pharmacist’s intervention led to significant decrease in erlotinib interactions which may result in treatment optimization of lung cancer patients.


  • Open Access

    Screening of undiagnosed depression among elderly primary care patients: a cross-sectional study from the Republic of Srpska, Bosnia and Herzegovina

    by Kosana Stanetić, Verica Petrović, Bojan Stanetić, Vesna Kević, Mirko Stanetić, Jelena Matović, Srebrenka Kusmuk, Maja Račić

    Aim To examine the prevalence of undiagnosed depression among primary care elderly patients in the entity of the Republic of Srpska (Bosnia and Herzegovina) as well as the sociodemographic and clinical risk factors associated with depression. Methods A cross-sectional study was conducted between April and June 2019 in nine towns of the Republic of Srpska. The study sample included 1,198 primary care patients older than 65 years of age. Research instruments included a sociodemographic questionnaire and Geriatric Depression Scale-Short Form (GDS-SF). Results Positive screening test (GDS-SF score > 5), which indicates depression was found in 484 (40.4%) participants. Multivariate regression analysis showed that lower education levels [OR = 1.565, 95% CI (1.13-2.17)], divorced and widowed [OR = 1.366, 95% CI (1.16-1.62)], poor financial situation [OR = 1.690 , 95% CI (1.25-2.29)], non-home residents [OR = 2.200, 95% CI (1.41-3.44)], non-hobby patients [OR = 2.115, 95% CI (1.54-2.91) ], non-friends [OR = 3.881, 95% CI (2.70-5.57)], patients suffering from chronic pain [OR = 2.414, 95% CI (1.72-3.39)], patients with daily life limitation activities [OR = 1.415, 95% CI (1.03-1.95)], patients with three or more chronic diseases [OR = 1.593, 95% CI (1.12-2.27)], patients using five or more drugs [OR = 1.425. 95% CI (1.00-2.03)], and patients with history of previous depression [OR = 2.858, 95% CI (1.94-4.21)] were at higher risk for depression. Conclusion The prevalence of undiagnosed depression in the elderly in Republic of Srpska is high. Future strategies are needed to strengthen screening of geriatric depression in primary health care.


  • Zastupljenost navike pušenja kod adolescenata

    by Kosana Stanetić, Slavica Trifković Perić, Mirko Stanetić